1
|
Caro-Vegas C, Peng A, Juarez A, Silverstein A, Kamiyango W, Villiera J, McAtee CL, Mzikamanda R, Tomoka T, Peckham-Gregory EC, Moorad R, Kovarik CL, Campbell LR, Mehta PS, Kazembe PN, Allen CE, Scheurer ME, Ozuah NW, Dittmer DP, El-Mallawany NK. Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease. JCI Insight 2023; 8:e167854. [PMID: 37991023 PMCID: PMC10721314 DOI: 10.1172/jci.insight.167854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 10/13/2023] [Indexed: 11/23/2023] Open
Abstract
BACKGROUNDKaposi sarcoma (KS) is among the most common childhood cancers in Eastern and Central Africa. Pediatric KS has a distinctive clinical presentation compared with adult KS, which includes a tendency for primary lymph node involvement, a considerable proportion of patients lacking cutaneous lesions, and a potential for fulminant disease. The molecular mechanisms or correlates for these disease features are unknown.METHODSThis was a cross-sectional study. All cases were confirmed by IHC for KS-associated herpesvirus (KSHV) LANA protein. Baseline blood samples were profiled for HIV and KSHV genome copy numbers by qPCR and secreted cytokines by ELISA. Biopsies were characterized for viral and human transcription, and KSHV genomes were determined when possible.RESULTSSeventy participants with pediatric KS were enrolled between June 2013 and August 2019 in Malawi and compared with adult patients with KS. They exhibited high KSHV genome copy numbers and IL-6/IL-10 levels. Four biopsies (16%) had a viral transcription pattern consistent with lytic viral replication.CONCLUSIONThe unique features of pediatric KS may contribute to the specific clinical manifestations and may direct future treatment options.FUNDINGUS National Institutes of Health U54-CA-254569, PO1-CA019014, U54-CA254564, RO1-CA23958.
Collapse
Affiliation(s)
- Carolina Caro-Vegas
- UNC Lineberger Comprehensive Cancer Center and Center for AIDS Research, Chapel Hill, North Carolina, USA
| | - Alice Peng
- UNC Lineberger Comprehensive Cancer Center and Center for AIDS Research, Chapel Hill, North Carolina, USA
| | - Angelica Juarez
- UNC Lineberger Comprehensive Cancer Center and Center for AIDS Research, Chapel Hill, North Carolina, USA
| | - Allison Silverstein
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- University of Colorado, Department of Pediatrics, Denver, Colorado, USA
| | - William Kamiyango
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
| | - Jimmy Villiera
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
| | - Casey L. McAtee
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Rizine Mzikamanda
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
| | - Tamiwe Tomoka
- University of North Carolina Project-Malawi, Kamuzu Central Hospital Pathology Laboratory, Lilongwe, Malawi
| | - Erin C. Peckham-Gregory
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Razia Moorad
- UNC Lineberger Comprehensive Cancer Center and Center for AIDS Research, Chapel Hill, North Carolina, USA
| | | | - Liane R. Campbell
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- BCM International Pediatric AIDS Initiative Children’s Foundation Tanzania, Mbeya, Tanzania
| | - Parth S. Mehta
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Peter N. Kazembe
- BCM International Pediatric AIDS Initiative Children’s Foundation Malawi, Lilongwe, Malawi
| | - Carl E. Allen
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Michael E. Scheurer
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Nmazuo W. Ozuah
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| | - Dirk P. Dittmer
- UNC Lineberger Comprehensive Cancer Center and Center for AIDS Research, Chapel Hill, North Carolina, USA
| | - Nader Kim El-Mallawany
- Texas Children’s Cancer & Hematology Center Global HOPE (Hematology-Oncology Pediatric Excellence) Program Malawi, Lilongwe, Malawi
- Baylor College of Medicine (BCM), Department of Pediatrics, Houston, Texas, USA
- Texas Children’s Hospital Cancer & Hematology Center, Houston, Texas, USA
| |
Collapse
|
2
|
Campbell LR, Silverstein A, Peckham-Gregory E, Kamiyango W, Villiera J, McAtee CL, Bacha JM, Kovarik CL, Mehta PS, Chanroo T, Kapesa A, Malingoti B, Mzikamanda R, Ozuah NW, Allen CE, Scheurer ME, El-Mallawany NK. Divergent clinical presentations and outcomes among children and adolescents with Kaposi sarcoma in Malawi and Tanzania. HIV Med 2023; 24:664-675. [PMID: 36627111 PMCID: PMC10257738 DOI: 10.1111/hiv.13455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 12/18/2022] [Indexed: 01/12/2023]
Abstract
OBJECTIVES The Kaposi sarcoma (KS) T0 versus T1 staging classification does not address the unique clinical features of paediatric KS in human gammaherpesvirus 8 (HHV-8) endemic regions of Africa. This study seeks to define patterns of childhood KS using a paediatric-specific approach. METHODS The Lilongwe paediatric KS staging classification categorizes disease based on clinical phenotype: stage 1 = mild/moderate KS limited to cutaneous/oral involvement, stage 2 = primarily lymphadenopathic disease, stage 3 = woody edema KS, stage 4 = visceral and/or severe/disseminated mucocutaneous disease. Characteristics and outcomes were evaluated from paediatric referral centres in Lilongwe, Malawi, and Mbeya, Tanzania. RESULTS Among 171 patients, the median age was 9.3 years, 37% (n = 63) were female, and 87% (n = 149) had HIV. Breakdown by stage was as follows: 18% (n = 31) stage 1, 33% (n = 56) stage 2, 19% (n = 33) stage 3, and 30% (n = 51) stage 4. Age (younger stage 2 and older stage 3), severe CD4 count suppression (lower CD4 for stages 1 and 4), and presence of severe anaemia and thrombocytopenia (worse for stages 2 and 4) differed across stages. Estimated 2-year event-free survival/progression-free survival/overall survival by stage was as follows: stage 1, 81%/81%/87%; stage 2, 50%/50%/63%; stage 3, 24%/49%/81%; and stage 4, 29%/34%/54%. Sub-analysis of stage 2 lymphadenopathic KS demonstrated superior long-term 6-year event-free survival of 70% (95% confidence interval [CI] 49-83) for younger children (aged <7 years) versus 27% (95% CI 8-51) for older children. CONCLUSIONS This paediatric-specific staging classification categorizes patients with distinct characteristics and patterns of treatment response. This platform may guide clinicians to provide risk-stratified treatment with the hope of improving survival among children with KS.
Collapse
Affiliation(s)
- Liane R. Campbell
- Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital, Houston, TX, USA
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation - Tanzania, Mbeya, Tanzania
| | - Allison Silverstein
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
| | - Erin Peckham-Gregory
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
| | - William Kamiyango
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
| | - Jimmy Villiera
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
| | - Casey L. McAtee
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
- Global HOPE, Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
| | - Jason M. Bacha
- Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital, Houston, TX, USA
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation - Tanzania, Mbeya, Tanzania
| | | | - Parth S. Mehta
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Global HOPE, Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
| | - Toni Chanroo
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
| | - Asulwisye Kapesa
- Baylor College of Medicine Children’s Foundation - Tanzania, Mbeya, Tanzania
| | - Beatrice Malingoti
- Baylor College of Medicine Children’s Foundation - Tanzania, Mbeya, Tanzania
| | - Rizine Mzikamanda
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
| | - Nmazuo W. Ozuah
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Texas Children’s Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Lilongwe, Malawi
- Global HOPE, Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
| | - Carl E. Allen
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Global HOPE, Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
| | - Michael E. Scheurer
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
| | - Nader Kim El-Mallawany
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- Global HOPE, Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
| |
Collapse
|
3
|
Endemic Kaposi's Sarcoma. Cancers (Basel) 2023; 15:cancers15030872. [PMID: 36765830 PMCID: PMC9913747 DOI: 10.3390/cancers15030872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 01/26/2023] [Accepted: 01/27/2023] [Indexed: 02/01/2023] Open
Abstract
Kaposi's sarcoma (KS) is a common neoplasm in Eastern and central Africa reflecting the spread of human gammaherpesvirus-8 (HHV-8), now considered a necessary causal agent for the development of KS. The endemic KS subtype can follow an aggressive clinical course with ulcerative skin lesions with soft tissue invasion or even bone or visceral involvement. In the latter cases, a thorough imaging work-up and better follow-up schedules are warranted. As KS is a chronic disease, the therapeutic goal is to obtain sustainable remission in cutaneous and visceral lesions and a good quality of life. Watchful monitoring may be sufficient in localized cutaneous forms. Potential therapeutic modalities for symptomatic advanced KS include systemic chemotherapies, immunomodulators, immune checkpoint inhibitors, and antiangiogenic drugs.
Collapse
|
4
|
Campbell LR, El-Mallawany NK, Slone JS, Malingoti BM, Mehta PS, Scheurer ME, Bacha JM, Peckham-Gregory EC. Clinical characteristics and successful treatment outcomes of children and adolescents with Kaposi sarcoma in Southwestern Tanzania. Pediatr Hematol Oncol 2022; 39:28-47. [PMID: 34243680 DOI: 10.1080/08880018.2021.1936315] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The HIV/AIDS epidemic has driven the rise in cases of Kaposi sarcoma (KS) among children and adolescents living with HIV in countries with high Human gammaherpesvirus 8 (HHV-8) seroprevalence, such as Tanzania, where specialized oncology programs are sparse. Consequently, descriptions of successful treatment of KS in children and adolescents by general pediatricians are important. A retrospective analysis was performed of children and adolescents diagnosed with KS and treated with chemotherapy and combination antiretroviral therapy (cART) at the Baylor College of Medicine Children's Foundation Tanzania Center of Excellence - Mbeya between 2011 and 2017. Sixty-one patients were diagnosed with KS with a median age of 12.6 years (interquartile range (IQR) 9.4 - 15.5). Diagnosis was confirmed by histopathology in 36% (22/61). Among HIV positive patients (59/61), 78% (46/59) were on cART at KS diagnosis. Severe immunosuppression was present in 63% (35/56) of those with CD4 data and 44% (27/61) had SAM. Advanced-stage T1 disease was present in 64% (39/61), including 28% (17/61) with visceral/disseminated KS. Two-year estimated overall survival (OS) was 72% (95% Confidence Interval (CI): 58%-82%) and median follow up for survivors was 25.7 months (IQR 14.2-53.8). No patients were lost to follow up. Two-year OS was 63% (95% CI: 44%-77%) in patients with severe immune suppression and 60% (95% CI: 37%-76%) in patients with SAM. Among patients with visceral/disseminated KS, 53% (9/17) survived. This retrospective analysis demonstrated favorable outcomes in a complex cohort of children and adolescents with KS treated with chemotherapy by general pediatricians in Tanzania.
Collapse
Affiliation(s)
- L R Campbell
- Baylor College of Medicine International Pediatric AIDS Initiative at, Texas Children's Hospital, Houston, Texas, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
| | - N K El-Mallawany
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA
| | - J S Slone
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA
| | - B M Malingoti
- Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA
| | - P S Mehta
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA
| | - M E Scheurer
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.,Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
| | - J M Bacha
- Baylor College of Medicine International Pediatric AIDS Initiative at, Texas Children's Hospital, Houston, Texas, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA
| | - E C Peckham-Gregory
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.,Global HOPE, Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.,Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
| |
Collapse
|
5
|
Silverstein A, Kamiyango W, Villiera J, Peckham-Gregory EC, McAtee CL, Scheurer ME, Cox CM, Kovarik CL, Campbell LR, Allen CE, Mehta PS, Kazembe PN, Ozuah NW, El-Mallawany NK. Long-term outcomes for children and adolescents with Kaposi sarcoma. HIV Med 2021; 23:197-203. [PMID: 34634187 DOI: 10.1111/hiv.13191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 08/27/2021] [Accepted: 09/23/2021] [Indexed: 01/28/2023]
Abstract
OBJECTIVES Kaposi sarcoma (KS) is one of the most common childhood cancers in eastern and central Africa. It has become a treatable disease with increasing availability of antiretroviral therapy (ART) and chemotherapy. We aimed to fill the data gap in establishing whether long-term survival is achievable for children in low-income countries. METHODS We retrospectively analysed data for children and adolescents aged ≤ 18.9 years diagnosed with HIV-related or endemic KS from 2006 to 2015 who received standardized institutional treatment regimens utilizing chemotherapy plus ART (if HIV-positive) at a tertiary care public hospital in Lilongwe, Malawi. Long-term survival was analysed and mortality was associated with KS for those with refractory/progressive disease at the time of death. RESULTS There were 207 children/adolescents with KS (90.8% HIV-related); 36.7% were alive, 54.6% had died, and 8.7% had been lost to follow-up. The median follow-up time for survivors was 6.9 years (range 4.2-13.9 years). Death occurred at a median of 5.3 months after KS diagnosis (range 0.1-123 months). KS progression was associated with mortality for most (61%) early deaths (survival time of < 6 months); conversely, KS was associated with a minority (31%) of late-onset deaths (after 24 months). The 7-year overall survival was 37% [95% confidence interval (CI) 30-44%] and was higher for those diagnosed between 2011 and 2015 compared to 2006-2010: 42% (95% CI 33-51%) versus 29% (95% CI 20-39%), respectively (P = 0.01). Among the 66 HIV-positive survivors, 58% were still on first-line ART. CONCLUSIONS Long-term survival is possible for pediatric KS in low-resource settings. Despite better survival in more recent years, there remains room for improvement.
Collapse
Affiliation(s)
- Allison Silverstein
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi.,Baylor College of Medicine, Houston, TX, USA
| | - William Kamiyango
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi
| | - Jimmy Villiera
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi
| | - Erin C Peckham-Gregory
- Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Casey L McAtee
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Michael E Scheurer
- Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Carrie M Cox
- Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi.,Baylor College of Medicine, Houston, TX, USA
| | | | - Liane R Campbell
- Baylor College of Medicine, Houston, TX, USA.,Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children's Hospital, Houston, TX, USA.,Baylor College of Medicine Children's Foundation Tanzania, Mbeya, Tanzania
| | - Carl E Allen
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Parth S Mehta
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Peter N Kazembe
- Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi
| | - Nmazuo W Ozuah
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Children's Foundation Malawi, Lilongwe, Malawi.,Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Nader Kim El-Mallawany
- Texas Children's Cancer and Hematology Centers Global HOPE (Hematology-Oncology Pediatric Excellence) Program, Houston, TX, USA.,Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| |
Collapse
|
6
|
Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi's Sarcoma Patients. Cancers (Basel) 2020; 12:cancers12061594. [PMID: 32560243 PMCID: PMC7352224 DOI: 10.3390/cancers12061594] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 06/07/2020] [Accepted: 06/12/2020] [Indexed: 12/26/2022] Open
Abstract
Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05 were considered significant. Subjects with patch and plaque KS lesions responded more favorably to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants with KS despite a clinical KS response. While patch and plaque KS lesions were more common among treatment responders, none of the analyzed viral and immunological parameters distinguished responders from non-responders at baseline or after treatment.
Collapse
|
7
|
Kamiyango W, Villiera J, Silverstein A, Peckham-Gregory E, Campbell LR, El-Mallawany NK. Navigating the heterogeneous landscape of pediatric Kaposi sarcoma. Cancer Metastasis Rev 2020; 38:749-758. [PMID: 31845111 DOI: 10.1007/s10555-019-09823-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Vivid descriptions of Kaposi sarcoma (KS) occurring in children and adolescents from central and eastern Africa originated over 50 years ago. Unique clinical characteristics of pediatric KS in Africa were well described within these geographic regions that were eventually understood to be endemic for human herpesvirus-8/Kaposi sarcoma herpesvirus (HHV-8/KSHV) infection, the causative agent of KS. Having catapulted in incidence with the HIV epidemic, KS is currently among the top five most common childhood cancers in numerous countries throughout the region. The main feature that differentiates the childhood form of KS from adult disease is clinical presentation with primarily bulging lymphadenopathy. This group of patients represents the most common clinical subtype of pediatric KS in KSHV-endemic regions. Lymphadenopathic KS in children is associated with other distinct features, such as sparse occurrence of prototypical hyperpigmented cutaneous lesions, frequent presentation with severe cytopenias and a normal CD4 count, and a fulminant clinical course if untreated with chemotherapy. Increased awareness and improved recognition of lymphadenopathic KS are critically important, particularly because this subset of patients typically experiences a favorable response to chemotherapy characterized by durable complete remission. Clinical phenotypes typically observed in adult KS also occur in children-mild/moderate disease limited to cutaneous and oral involvement, woody edema, and visceral disease. This review summarizes the heterogeneous patterns of disease presentation and treatment response observed among the divergent clinical phenotypes of pediatric KS, highlights additional KSHV-related malignancies, and explores some of the potential biological drivers of such clinical phenomena.
Collapse
Affiliation(s)
- William Kamiyango
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi.,Texas Children's Cancer and Hematology Centers Global HOPE Program, Lilongwe, Malawi
| | - Jimmy Villiera
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi.,Texas Children's Cancer and Hematology Centers Global HOPE Program, Lilongwe, Malawi
| | - Allison Silverstein
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi.,Texas Children's Cancer and Hematology Centers Global HOPE Program, Lilongwe, Malawi.,Baylor College of Medicine, Houston, TX, USA
| | - Erin Peckham-Gregory
- Baylor College of Medicine, Houston, TX, USA.,Global HOPE (Hematology-Oncology Pediatric Excellence), Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, 1102 Bates Street, Feigin Tower, Room 1025.16, Houston, TX, 77030, USA
| | - Liane R Campbell
- Baylor College of Medicine, Houston, TX, USA.,Baylor College of Medicine Children's Foundation Tanzania, Mbeya, Tanzania
| | - Nader Kim El-Mallawany
- Baylor College of Medicine, Houston, TX, USA. .,Global HOPE (Hematology-Oncology Pediatric Excellence), Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, 1102 Bates Street, Feigin Tower, Room 1025.16, Houston, TX, 77030, USA.
| |
Collapse
|
8
|
Abstract
Kaposi’s sarcoma (KS) is a vascular tumour of endothelial origin that is associated with human herpes virus-8 infection. In sub-Saharan Africa, AIDS-KS remains the most common HIV-associated malignancy, and hence it poses a huge burden to the already constrained health-care systems. KS has four clinical variants, namely, classic, endemic, iatrogenic and epidemic KS. The histopathology in these different KS forms is essentially identical; however, they have different clinical patterns. Expanding knowledge of KS biology increases hope for prevention, disease control, and hence better quality of life among patients. Primary prevention strategy for KS-associated herpes virus and management of disease complication, such as lymphoedema should be the focus of disease-prevention and -control research.
Collapse
Affiliation(s)
- Jackson Orem
- Uganda Cancer Institute, Upper Mulago Hill Road, PO Box 3935, Kampala, Uganda
| |
Collapse
|
9
|
Chelidze K, Thomas C, Chang AY, Freeman EE. HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management. Am J Clin Dermatol 2019; 20:423-442. [PMID: 30806959 DOI: 10.1007/s40257-019-00422-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Antiretroviral therapy (ART) has revolutionized the treatment and prognosis of people living with HIV (PLHIV). With increased survival and improved overall health, PLHIV are experiencing dermatologic issues both specific to HIV and common to the general population. In this new era of ART, it is crucial for dermatologists to have a strong understanding of the broad range of cutaneous disease and treatment options in this unique population. In this review, we outline the most common skin diseases in PLHIV, including HIV-associated malignancies, inflammatory conditions, and infections, and focus on the role of ART in altering epidemiology, clinical features, diagnosis, and treatment of cutaneous conditions.
Collapse
Affiliation(s)
- Khatiya Chelidze
- Weill Cornell Medical College, Massachusetts General Hospital, 1300 York Avenue, New York, NY, 10021, USA
| | - Cristina Thomas
- Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Bartlett Hall 6R, Boston, MA, 02114, USA
| | - Aileen Yenting Chang
- Department of Dermatology, University of California, San Francisco, 505 Paranassus Avenue, San Francisco, CA, 94143, USA
| | - Esther Ellen Freeman
- Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Bartlett Hall 6R, Boston, MA, 02114, USA.
- Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA, 02114, USA.
| |
Collapse
|
10
|
El-Mallawany NK, Villiera J, Kamiyango W, Peckham-Gregory EC, Scheurer ME, Allen CE, McAtee CL, Legarreta A, Dittmer DP, Kovarik CL, Chiao EY, Martin SC, Ozuah NW, Mehta PS, Kazembe PN. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer 2018; 13:33. [PMID: 30455728 PMCID: PMC6230225 DOI: 10.1186/s13027-018-0207-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 10/31/2018] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND Endemic Kaposi sarcoma (KS) was first described in African children over fifty years ago, but has recently been overshadowed by HIV-related disease. We aimed to evaluate the similarities and differences between endemic HIV-negative and epidemic HIV-positive pediatric KS in a KS-associated herpesvirus-endemic region of Africa. METHODS We describe clinical characteristics of 20 HIV-negative children with endemic KS over a six-year period and compare findings with a historical control-an HIV-related pediatric KS cohort from Lilongwe, Malawi. RESULTS The HIV-negative endemic KS cohort was 70% male with a median age of 9.3 years. Lymph node involvement was present in 50%, hyperpigmented skin lesions in 45%, and woody edema in 40%. One patient (5%) presented with oral KS involvement and no patients presented initially with visceral KS. Significant anemia (hemoglobin < 8 g/dL) and thrombocytopenia (platelet count < 100 × 109/L) were found at time of original KS diagnosis in 45 and 40% respectively. In both HIV-negative and HIV-positive cohorts, lymphadenopathy was the most common presentation, prototypical skin lesions were often absent, severe cytopenias were a common clinical feature, and treatment outcomes were similar. Patients with endemic KS demonstrated less frequent oral involvement (5% versus 29%, P = 0.03) and a lower proportion of patients with visceral involvement (0% versus 16%, P = 0.06). CONCLUSIONS These data suggest clinical overlap between epidemiological variants. Treatment protocols for pediatric KS in sub-Saharan Africa should be devised to include both endemic HIV-negative and epidemic HIV-related disease to better define the clinical and biological comparison.
Collapse
Affiliation(s)
- Nader Kim El-Mallawany
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Jimmy Villiera
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Kamuzu Central Hospital, Lilongwe, Malawi
| | - William Kamiyango
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Kamuzu Central Hospital, Lilongwe, Malawi
| | - Erin C. Peckham-Gregory
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Michael E. Scheurer
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Carl E. Allen
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Casey L. McAtee
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Alejandra Legarreta
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Dirk P. Dittmer
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC USA
| | | | - Elizabeth Y. Chiao
- Center for Innovation, Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX USA
- Baylor College of Medicine, Department of Medicine, Section of Infectious Diseases, Houston, TX USA
| | - Stephen C. Martin
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
| | - Nmazuo W. Ozuah
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Parth S. Mehta
- Baylor College of Medicine, Department of Pediatrics, Section of Hematology-Oncology, Houston, TX USA
- Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Global HOPE (Hematology-Oncology Pediatric Excellence), 1102 Bates Street, Feigin Tower, Suite 1025.16, Houston, TX 77030 USA
| | - Peter N. Kazembe
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Kamuzu Central Hospital, Lilongwe, Malawi
| |
Collapse
|
11
|
El-Mallawany NK, Mehta PS, Kamiyango W, Villiera J, Peckham-Gregory EC, Kampani C, Krysiak R, Sanders MK, Caro-Vegas C, Eason AB, Ahmed S, Schutze GE, Martin SC, Kazembe PN, Scheurer ME, Dittmer DP. KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. Int J Cancer 2018; 144:110-116. [PMID: 30204240 DOI: 10.1002/ijc.31863] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 08/15/2018] [Accepted: 08/23/2018] [Indexed: 01/12/2023]
Abstract
Kaposi sarcoma (KS) is among the most common childhood malignancies in central, eastern, and southern Africa. Although its unique clinical features have been established, biological mechanisms related to the causative agent, KS-associated herpes-virus (KSHV), have yet to be explored in children. We performed a prospective observational pilot study to explore associations between KSHV viral load (VL), human interleukin-6 (IL-6) and IL-10 levels, and clinical characteristics of 25 children with KS in Lilongwe, Malawi from June 2013-August 2015. The median age was 6.4 years. Lymphadenopathy was the most common site of KS involvement (64%), followed by skin and oral mucosa (44% each), woody edema (12%), and pulmonary (8%). Baseline samples for plasma KSHV VL, IL-6 and IL-10 analyses were available for 18/25 patients (72%) at time of KS diagnosis. KSHV VL was detectable at baseline in 12/18 (67%) patients, the median baseline IL-6 level was 8.53 pg/mL (range 4.31-28.33), and the median baseline IL-10 level was 19.53 pg/mL (range 6.91-419.69). Seven (39%) patients presented with an IL-6 level > 10 pg/mL (exceeding twice the upper limit of normal). Detectable KSHV VL was significantly associated with lymphadenopathic KS (p = 0.004), while having undetectable KSHV VL was associated with a higher likelihood of presenting with hyperpigmented skin lesions (p = 0.01). Detectable KSHV VL and elevated IL-6 levels are present in a subset of children with KS. Lytic activation of KSHV and associated elevation in KSHV VL may contribute to the unique clinical manifestations of pediatric KS in KSHV-endemic regions of Africa.
Collapse
Affiliation(s)
- Nader Kim El-Mallawany
- Baylor College of Medicine, Houston, TX.,Texas Children's Cancer and Hematology Centers, Houston, TX
| | - Parth S Mehta
- Baylor College of Medicine, Houston, TX.,Texas Children's Cancer and Hematology Centers, Houston, TX
| | - William Kamiyango
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi
| | - Jimmy Villiera
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi
| | - Erin C Peckham-Gregory
- Baylor College of Medicine, Houston, TX.,Texas Children's Cancer and Hematology Centers, Houston, TX
| | - Coxcilly Kampani
- University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi
| | - Robert Krysiak
- University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi
| | | | | | - Anthony B Eason
- Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC
| | - Saeed Ahmed
- Baylor College of Medicine, Houston, TX.,Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi
| | - Gordon E Schutze
- Baylor College of Medicine, Houston, TX.,Texas Children's Hospital, Houston, TX
| | - Stephen C Martin
- Baylor College of Medicine, Houston, TX.,Texas Children's Cancer and Hematology Centers, Houston, TX.,Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi
| | - Peter N Kazembe
- Baylor College of Medicine Children's Foundation Malawi, Lilongwe, Malawi
| | - Michael E Scheurer
- Baylor College of Medicine, Houston, TX.,Texas Children's Cancer and Hematology Centers, Houston, TX
| | - Dirk P Dittmer
- Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC
| |
Collapse
|
12
|
El-Mallawany NK, McAtee CL, Campbell LR, Kazembe PN. Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS 2018; 9:35-46. [PMID: 29722363 PMCID: PMC5919159 DOI: 10.2147/phmt.s142816] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The global experience with pediatric Kaposi sarcoma (KS) has evolved immensely since the onset of HIV (human immunodeficiency virus). In this review, current perspectives on childhood KS are discussed in the context of the HIV epidemic in sub-Saharan Africa. Endemic (HIV-unrelated) KS was first described over 50 years ago in central and eastern Africa, regions where human herpesvirus-8, the causative agent of KS, is endemic. With the alarming rise in HIV prevalence over the past few decades, KS has become not only the most common HIV-related malignancy in Africa, but also one of the most common overall childhood cancers throughout the central, eastern, and southern regions of the continent. The unique clinical features of pediatric KS that were described in those early endemic KS reports have been re-affirmed by the contemporary experience with HIV-related KS. These characteristics include a predilection for primary lymph node involvement, significant proportions of patients lacking prototypical cutaneous lesions, and the potential for fulminant disease progression. Other clinical features that distinguish childhood KS from adult disease include disease presentation with severe cytopenias, and the common occurrence of childhood KS without severe CD4 count suppression. Distinct clinical heterogeneity in disease presentation and treatment response have been demonstrated. Long-term complete remission and event-free survival can be achieved—especially in children with lymphadenopathic KS—utilizing treatment with antiretroviral therapy plus mild–moderate chemotherapy regimens that are well tolerated, even in low-income settings. A pediatric-specific staging classification and risk-stratification platform have been retrospectively validated, and may help guide therapeutic strategies. With expansion of the HIV treatment infrastructure throughout Africa, coupled with recent developments in establishing comprehensive pediatric oncology programs, there is great potential for improving outcomes for children with KS. Increased awareness of the unique clinical nuances and collaborative evaluations of pediatric-specific treatment paradigms are required to optimize survival for children with KS.
Collapse
Affiliation(s)
- Nader Kim El-Mallawany
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Casey L McAtee
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Houston, TX, USA
| | - Liane R Campbell
- Department of Pediatrics, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania
| | - Peter N Kazembe
- Department of Pediatrics, Baylor College of Medicine Children's Foundation Malawi, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Lilongwe, Malawi.,Department of Pediatrics, Kamuzu Central Hospital, Lilongwe, Malawi
| |
Collapse
|
13
|
Macken M, Dale H, Moyo D, Chakmata E, Depani S, Israels T, Niyrenda D, Bailey S, Chagaluka G, Molyneux EM. Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. Pediatr Blood Cancer 2018; 65. [PMID: 28988435 DOI: 10.1002/pbc.26841] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Accepted: 09/05/2017] [Indexed: 11/11/2022]
Abstract
BACKGROUND Kaposi sarcoma (KS) is the most common paediatric cancer in human immunodeficiency virus (HIV) endemic countries of sub-Saharan Africa, but there is little research on management and outcomes. METHODS Children with KS at Queen Elizabeth Central Hospital, Blantyre, Malawi treated between August 2012 and March 2015 with six courses of vincristine, bleomycin and etoposide combination chemotherapy, including antiretroviral therapy (ART) if HIV infected, were studied and outcomes compared with previously reported results. FINDINGS Fifty-six children were included; 38 (68%) were male; and 48 (86%) were HIV positive, of whom 36 (77%) were on ART at diagnosis. Median age at diagnosis was 8 years (interquartile range [IQR] 3-12) and median follow-up was 16.9 months (IQR 3.4-36.4). Quality of life improved in 45 (80%) children; the median Lansky Score increased from 80% pre-treatment to 100% post-treatment. Eighteen (32%) children had complete response to treatment. At 12 months, overall survival was 71% (95% confidence interval [CI] 56-82) and event-free survival (event = death, loss to follow-up or relapse) was 50% (95% CI 36-63). At 1 year, the risk of loss to follow-up was 13.4%. In a previous, same-site, randomized controlled study of vincristine monotherapy, vincristine and bleomycin, or oral etoposide, oral etoposide monotherapy had the best outcome with survival at 12 month of 66% (95% CI 46-80) and event-free survival of 52% (95% CI 33-68); however, loss to follow-up was not reported. CONCLUSION Overall survival, event-free survival and quality of life appear to have improved with this three-agent combination chemotherapy; however larger, randomized studies are needed to determine optimal management.
Collapse
Affiliation(s)
- Marita Macken
- Department of Paediatric Oncology, Birmingham Children's Hospital, Birmingham, UK
| | - Helen Dale
- Sheffield Children's Hospital, Sheffield, UK
| | - Dominic Moyo
- Queen Elizabeth Central Hospital, College of Medicine, Blantyre, Malawi
| | - Eunice Chakmata
- Queen Elizabeth Central Hospital, College of Medicine, Blantyre, Malawi
| | | | - Trijn Israels
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Dalida Niyrenda
- Queen Elizabeth Central Hospital, College of Medicine, Blantyre, Malawi
| | - Simon Bailey
- Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, UK
| | - George Chagaluka
- Queen Elizabeth Central Hospital, College of Medicine, Blantyre, Malawi
| | | |
Collapse
|
14
|
El-Mallawany NK, Kamiyango W, Villiera J, Slone JS, Kovarik CL, Campbell LR, Agrawal AK, Dittmer DP, Eason AB, Ahmed S, Schutze GE, Scheurer ME, Kazembe PN, Mehta PS. Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol 2017; 4:1-7. [PMID: 29272148 PMCID: PMC6180767 DOI: 10.1200/jgo.17.00054] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Affiliation(s)
- Nader Kim El-Mallawany
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - William Kamiyango
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Jimmy Villiera
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Jeremy S Slone
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Carrie L Kovarik
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Liane R Campbell
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Anurag K Agrawal
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Dirk P Dittmer
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Anthony B Eason
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Saeed Ahmed
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Gordon E Schutze
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Michael E Scheurer
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Peter N Kazembe
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Parth S Mehta
- Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S. Mehta, Baylor College of Medicine; Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, and Parth S. Mehta, Texas Children's Cancer and Hematology Centers, Houston, TX; William Kamiyango, Jimmy Villiera, Saeed Ahmed, and Peter N. Kazembe, Baylor College of Medicine Children's Foundation Malawi; William Kamiyango, Jimmy Villiera, and Peter N. Kazembe, Kamuzu Central Hospital, Lilongwe, Malawi; Carrie L. Kovarik, University of Pennsylvania, Philadelphia, PA; Liane R. Campbell, Baylor College of Medicine Children's Foundation Tanzania, Baylor International Pediatric AIDS Initiative at Texas Children's Hospital, Mbeya, Tanzania; Anurag K. Agrawal, Children's Hospital and Research Center Oakland, Oakland, CA; and Dirk P. Dittmer and Anthony B. Eason, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| |
Collapse
|
15
|
Abstract
Skin tumors are a clinically heterogeneous group of dermatologic conditions that affect both children and adults. Although similar types of skin tumors can affect both children and adults, the epidemiology, pathogenesis, and treatment of these skin neoplasms can vary drastically in children compared with adults. Despite the clear need for literature elucidating the differences of skin tumors in children compared with adults, there is a serious dearth of scientific contributions addressing this area. This contribution highlights the types of differences that can occur between adults and children with skin neoplasms, as well as the special considerations that need to be recognized when managing skin tumors in children by providing a comparative analysis of basal cell carcinoma, squamous cell carcinoma, and Kaposi sarcoma occurring in adults with these same tumors occurring in children. Specifically, we examine the aforementioned tumors with a focus on (1) epidemiology, (2) etiology, (3) clinical presentation, (4) workup, and (5) treatment.
Collapse
MESH Headings
- Acquired Immunodeficiency Syndrome/complications
- Adolescent
- Adult
- Carcinoma, Basal Cell/diagnosis
- Carcinoma, Basal Cell/epidemiology
- Carcinoma, Basal Cell/etiology
- Carcinoma, Basal Cell/therapy
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/epidemiology
- Carcinoma, Squamous Cell/etiology
- Carcinoma, Squamous Cell/therapy
- Child
- Child, Preschool
- Humans
- Infant
- Infant, Newborn
- Sarcoma, Kaposi/diagnosis
- Sarcoma, Kaposi/etiology
- Sarcoma, Kaposi/therapy
- Skin Neoplasms/diagnosis
- Skin Neoplasms/epidemiology
- Skin Neoplasms/etiology
- Skin Neoplasms/therapy
Collapse
Affiliation(s)
- Reid A Waldman
- Department of Dermatology, University of Connecticut Health Center, Farmington, CT
| | - Jane M Grant-Kels
- Department of Dermatology, University of Connecticut Health Center, Farmington, CT.
| |
Collapse
|
16
|
Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, Obel N, Grabar S, Verbon A, Noguera-Julian A, Collins IJ, Rojo P, Brockmeyer N, Campbell M, Chêne G, Prozesky H, Eley B, Stefan DC, Davidson A, Chimbetete C, Sawry S, Davies MA, Kariminia A, Vibol U, Sohn A, Egger M, Bohlius J. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clin Infect Dis 2016; 63:1245-1253. [PMID: 27578823 PMCID: PMC5064163 DOI: 10.1093/cid/ciw519] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 07/21/2016] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV)-infected children and adolescents on combination antiretroviral therapy (cART) has not been compared globally. METHODS We analyzed cohort data from the International Epidemiologic Databases to Evaluate AIDS and the Collaboration of Observational HIV Epidemiological Research in Europe. We included HIV-infected children aged <16 years at cART initiation from 1996 onward. We used Cox models to calculate hazard ratios (HRs), adjusted for region and origin, sex, cART start year, age, and HIV/AIDS stage at cART initiation. RESULTS We included 24 991 children from eastern Africa, southern Africa, Europe and Asia; 26 developed KS after starting cART. Incidence rates per 100 000 person-years (PYs) were 86 in eastern Africa (95% confidence interval [CI], 55-133), 11 in southern Africa (95% CI, 4-35), and 81 (95% CI, 26-252) in children of sub-Saharan African (SSA) origin in Europe. The KS incidence rates were 0/100 000 PYs in children of non-SSA origin in Europe (95% CI, 0-50) and in Asia (95% CI, 0-27). KS risk was lower in girls than in boys (adjusted HR [aHR], 0.3; 95% CI, .1-.9) and increased with age (10-15 vs 0-4 years; aHR, 3.4; 95% CI, 1.2-10.1) and advanced HIV/AIDS stage (CDC stage C vs A/B; aHR, 2.4; 95% CI, .8-7.3) at cART initiation. CONCLUSIONS HIV-infected children from SSA but not those from other regions, have a high risk of developing KS after cART initiation. Early cART initiation in these children might reduce KS risk.
Collapse
|
17
|
Rees CA, Keating EM, Lukolyo H, Danysh HE, Scheurer ME, Mehta PS, Lubega J, Slone JS. Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A Review. Pediatr Blood Cancer 2016; 63:1325-31. [PMID: 27082516 PMCID: PMC7340190 DOI: 10.1002/pbc.26021] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 03/21/2016] [Accepted: 03/25/2016] [Indexed: 01/03/2023]
Abstract
Children with human immunodeficiency virus (HIV) have an increased risk of developing Kaposi Sarcoma (KS) and non-Hodgkin lymphoma (NHL) compared to HIV-negative children. We compiled currently published epidemiologic data on KS and NHL among children in sub-Saharan Africa (SSA). Among countries with available data, the median incidence of KS was 2.05/100,000 in the general pediatric population and 67.35/100,000 among HIV-infected children. The median incidence of NHL was 1.98/100,000 among the general pediatric population, while data on NHL incidence among HIV-infected children were lacking. Larger regional studies are needed to better address the dearth of epidemiologic information on pediatric KS and NHL in SSA.
Collapse
Affiliation(s)
- Chris A Rees
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA
| | - Elizabeth M Keating
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA
| | - Heather Lukolyo
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA
| | - Heather E. Danysh
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA,Texas Children’s Cancer and Hematology Centers, Houston, TX, USA
| | - Michael E Scheurer
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA,Texas Children’s Cancer and Hematology Centers, Houston, TX, USA
| | - Parth S Mehta
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA,Texas Children’s Cancer and Hematology Centers, Houston, TX, USA
| | - Joseph Lubega
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA,Texas Children’s Cancer and Hematology Centers, Houston, TX, USA
| | - Jeremy S Slone
- Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA,Texas Children’s Cancer and Hematology Centers, Houston, TX, USA
| | | |
Collapse
|
18
|
Feiterna-Sperling C, Königs C, Notheis G, Buchholz B, Krüger R, Weizsäcker K, Eberle J, Hanhoff N, Gärtner B, Heider H, Krüger DH, Hofmann J. High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population. Med Microbiol Immunol 2016; 205:425-34. [PMID: 27240652 DOI: 10.1007/s00430-016-0458-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 05/09/2016] [Indexed: 11/28/2022]
Abstract
Human herpesvirus-8 (HHV-8) is the etiological agent of Kaposi's sarcoma (KS), which primarily affects human immunodeficiency virus (HIV)-infected adults with advanced immunodeficiency. Currently, only limited prevalence data for HHV-8 infection in HIV-infected children living in non-endemic areas are available. This multicenter cross-sectional study was conducted in four university hospitals in Germany specializing in pediatric HIV care. Stored serum specimens obtained from 207 vertically HIV-1-infected children and adolescents were tested for antibodies against lytic and latent HHV-8 antigens. Logistic regression was used to assess independent risk factors associated with HHV-8 seropositivity. The overall HHV-8 seroprevalence was 24.6 % (n = 51/207) without significant differences related to sex, age, or ethnicity. In univariate analysis, HHV-8 seropositivity was significantly associated with a child having being born outside Germany, maternal origin from sub-Saharan Africa, a history of breastfeeding, CDC immunologic category 3, and deferred initiation of antiretroviral therapy (>24 months of age). In multivariate analysis, a child's birth outside Germany was the only significant risk factor for HHV-8 seropositivity (odds ratio 3.98; 95 % confidence interval 1.27-12.42). HHV-8-associated malignancies were uncommon; only one patient had a history of KS. Serum specimen of vertically HIV-infected children and adolescents living in Germany showed a high HHV-8 seroprevalence. These findings suggest that primary HHV-8 infection-a risk factor for KS and other HHV-8-associated malignancies-occurs early in life. Thus, management of perinatally HIV-infected children should include testing for HHV-8 coinfection and should consider future risks of HHV-8-associated malignancies.
Collapse
Affiliation(s)
- Cornelia Feiterna-Sperling
- Department of Pediatric Pneumology and Immunology, Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
| | - Christoph Königs
- Department of Pediatrics, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Gundula Notheis
- Ludwig-Maximilians-University of Munich, Dr. von Haunersches Kinderspital, Munich, Germany
| | - Bernd Buchholz
- Medical Faculty Mannheim, University Children's Hospital, Heidelberg University, Heidelberg, Germany
| | - Renate Krüger
- Department of Pediatric Pneumology and Immunology, Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
| | | | - Josef Eberle
- Max von Pettenkofer-Institut, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - Nikola Hanhoff
- German Association of Physicians in HIV Care, Berlin, Germany
| | - Barbara Gärtner
- Institute of Microbiology and Hygiene, University of Saarland Medical School, Homburg/Saar, Germany
| | - Harald Heider
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité University Medicine Berlin, Berlin, Germany
| | - Detlev H Krüger
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité University Medicine Berlin, Berlin, Germany
| | - Jörg Hofmann
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité University Medicine Berlin, Berlin, Germany
| |
Collapse
|
19
|
El-Mallawany NK, Kamiyango W, Slone JS, Villiera J, Kovarik CL, Cox CM, Dittmer DP, Ahmed S, Schutze GE, Scheurer ME, Kazembe PN, Mehta PS. Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. PLoS One 2016; 11:e0153335. [PMID: 27082863 PMCID: PMC4833299 DOI: 10.1371/journal.pone.0153335] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 03/28/2016] [Indexed: 01/09/2023] Open
Abstract
Kaposi sarcoma (KS) is the most common HIV-associated malignancy in children and adolescents in Africa. Pediatric KS is distinct from adult disease. We evaluated the clinical characteristics associated with long-term outcomes. We performed a retrospective observational analysis of 70 HIV-infected children and adolescents with KS less than 18 years of age diagnosed between 8/2010 and 6/2013 in Lilongwe, Malawi. Local first-line treatment included bleomycin and vincristine plus nevirapine-based highly active anti-retroviral therapy (HAART). Median age was 8.6 years (range 1.7–17.9); there were 35 females (50%). Most common sites of presentation were: lymph node (74%), skin (59%), subcutaneous nodules (33%), oral (27%), woody edema (24%), and visceral (16%). Eighteen (26%) presented with lymphadenopathy only. Severe CD4 suppression occurred in 28%. At time of KS diagnosis, 49% were already on HAART. Overall, 28% presented with a platelet count < 100 x 109/L and 37% with hemoglobin < 8 g/dL. The 2-year event-free (EFS) and overall survival (OS) were 46% and 58% respectively (median follow-up 29 months, range 15–50). Multivariable analysis of risk of death and failure to achieve EFS demonstrated that visceral disease (odds ratios [OR] 19.08 and 11.61, 95% CI 2.22–163.90 and 1.60–83.95 respectively) and presenting with more than 20 skin/oral lesions (OR 9.57 and 22.90, 95% CI 1.01–90.99 and 1.00–524.13 respectively) were independent risk factors for both. Woody edema was associated with failure to achieve EFS (OR 7.80, 95% CI 1.84–33.08) but not death. Univariable analysis revealed that lymph node involvement was favorable for EFS (OR 0.28, 95% CI 0.08–0.99), while T1 TIS staging criteria, presence of cytopenias, and severe immune suppression were not associated with increased mortality. Long-term complete remission is achievable in pediatric KS, however outcomes vary according to clinical presentation. Based on clinical heterogeneity, treatment according to risk-stratification is necessary to improve overall outcomes.
Collapse
Affiliation(s)
- Nader Kim El-Mallawany
- Department of Pediatrics, Division of Hematology, Oncology, and Hematopoietic Stem Cell Transplantation, New York Medical College, Valhalla, New York, United States of America
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, United States of America
- * E-mail:
| | - William Kamiyango
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
| | - Jeremy S. Slone
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, United States of America
- Texas Children’s Cancer and Hematology Centers, Houston, Texas, United States of America
| | - Jimmy Villiera
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
| | - Carrie L. Kovarik
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Carrie M. Cox
- Department of Pediatrics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, United States of America
| | - Dirk P. Dittmer
- Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - Saeed Ahmed
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America
| | - Gordon E. Schutze
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America
| | - Michael E. Scheurer
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, United States of America
- Texas Children’s Cancer and Hematology Centers, Houston, Texas, United States of America
| | - Peter N. Kazembe
- Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi
| | - Parth S. Mehta
- Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, United States of America
- Texas Children’s Cancer and Hematology Centers, Houston, Texas, United States of America
| |
Collapse
|
20
|
Jackson CC, Dickson MA, Sadjadi M, Gessain A, Abel L, Jouanguy E, Casanova J. Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. Pediatr Blood Cancer 2016; 63:392-7. [PMID: 26469702 PMCID: PMC4984265 DOI: 10.1002/pbc.25779] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 09/04/2015] [Accepted: 09/10/2015] [Indexed: 12/13/2022]
Abstract
Kaposi sarcoma (KS) is an endothelial malignancy caused by human herpes virus-8 (HHV-8) infection. The epidemic and iatrogenic forms of childhood KS result from a profound and acquired T cell deficiency. Recent studies have shown that classic KS of childhood can result from rare single-gene inborn errors of immunity, with mutations in WAS, IFNGR1, STIM1, and TNFRSF4. The pathogenesis of the endemic form of childhood KS has remained elusive. We review childhood KS pathogenesis and its relationship to inherited and acquired immunodeficiency to oncogenic HHV-8.
Collapse
Affiliation(s)
- Carolyn C. Jackson
- St. Giles Laboratory of Human Genetics of Infectious DiseasesRockefeller BranchThe Rockefeller UniversityNew York
- Department of PediatricsMemorial Sloan Kettering Cancer CenterNew York
| | - Mark A. Dickson
- Department of MedicineMemorial Sloan Kettering Cancer CenterNew York
- Department of MedicineWeill Cornell Medical CollegeNew York
| | - Mahan Sadjadi
- St. Giles Laboratory of Human Genetics of Infectious DiseasesRockefeller BranchThe Rockefeller UniversityNew York
| | - Antoine Gessain
- Unit of Epidemiology and Physiopathology of Oncogenic VirusesInstitut PasteurParisFrance
| | - Laurent Abel
- St. Giles Laboratory of Human Genetics of Infectious DiseasesRockefeller BranchThe Rockefeller UniversityNew York
- Laboratory of Human Genetics of Infectious DiseasesNecker BranchINSERM U1163ParisFrance
- Paris Descartes UniversityImagine InstituteParisFrance
| | - Emmanuelle Jouanguy
- St. Giles Laboratory of Human Genetics of Infectious DiseasesRockefeller BranchThe Rockefeller UniversityNew York
- Laboratory of Human Genetics of Infectious DiseasesNecker BranchINSERM U1163ParisFrance
- Paris Descartes UniversityImagine InstituteParisFrance
| | - Jean‐Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious DiseasesRockefeller BranchThe Rockefeller UniversityNew York
- Laboratory of Human Genetics of Infectious DiseasesNecker BranchINSERM U1163ParisFrance
- Paris Descartes UniversityImagine InstituteParisFrance
- Howard Hughes Medical Institute
- Pediatric Hematology‐Immunology UnitNecker Hospital for Sick ChildrenParisFrance
| |
Collapse
|
21
|
Gantt S, Orem J, Krantz EM, Morrow RA, Selke S, Huang ML, Schiffer JT, Jerome KR, Nakaganda A, Wald A, Casper C, Corey L. Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. J Infect Dis 2016; 214:36-44. [PMID: 26917575 DOI: 10.1093/infdis/jiw076] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Accepted: 02/18/2016] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Human herpesvirus (HHV) infections are common during infancy. Primary infections are frequently asymptomatic and best studied prospectively by using direct viral detection. METHODS Oropharyngeal swab specimens were collected weekly from Ugandan newborn infants, their mothers, and other children in the household. Blood specimens were collected every 4 months. Samples were tested for herpes simplex virus (HSV) types 1 and 2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), HHV-6A, HHV-6B, and HHV-8, using quantitative polymerase chain reaction. RESULTS Thirty-two infants, 32 mothers, and 49 other household children were followed for a median of 57 weeks. Seventeen mothers had human immunodeficiency virus type 1 (HIV) infection; no infants acquired HIV-1. The 12-month incidence of postnatal infection was 76% for HHV-6B, 59% for CMV, 47% for EBV, 8% for HSV-1, and 0% for HHV-8. The quantity of oropharyngeal shedding by contacts was associated with HHV-6A or HHV-6B transmission. Maternal HIV-1 infection was associated with EBV transmission, while breastfeeding and younger child contacts were associated with CMV transmission. Except for HSV-1, primary HHV infections were subclinical. CONCLUSIONS By capturing exposures and acquisition events, we found that the incidence and risk factors of infection vary by HHV type. HSV-1 infection, unlike other HHV infections, caused acute clinical illness in these infants.
Collapse
Affiliation(s)
- Soren Gantt
- University of British Columbia, Child and Family Research Institute, Vancouver, Canada Fred Hutchinson Cancer Research Center
| | | | | | | | | | - Meei-Li Huang
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| | - Joshua T Schiffer
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| | - Keith R Jerome
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| | | | - Anna Wald
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| | - Corey Casper
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| | - Lawrence Corey
- Fred Hutchinson Cancer Research Center University of Washington, Seattle
| |
Collapse
|
22
|
Mittermayer-Vassallo K, Banda K, Molyneux EM. Kaposi sarcoma in HIV-seronegative children presenting to the paediatric oncology ward in The Queen Elizabeth Central Hospital, Blantyre, Malawi during 2002-2014. Trop Doct 2015; 46:138-42. [PMID: 26620689 DOI: 10.1177/0049475515614738] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
One of the most common malignancies in HIV-endemic, resource-poor countries is Kaposi sarcoma (KS). It is an AIDS-defining disease and as Malawi's incidence and prevalence of HIV is high, KS is now the most common cancer in adult male Malawians and the second most common in women and children. Most attention has focused on HIV-seropositive adults as their number far outweighs those of children. This audit concerns the presentation and outcome of HIV-seronegative children with KS who presented in a 12-year period (2002-2014) to The Queen Elizabeth Central Hospital. Twenty (10.5%) of the 191 children with KS presenting to the paediatric oncology ward during 2002-2014 were HIV-seronegative. They were usually younger than seropositive children and 62% had severe anaemia. The main presenting complaints in the HIV-seronegative group were woody oedema, commonly of a limb, and lymphadenopathy. Woody oedema was common in children with or without HIV infection. Seronegative children with KS were less likely to have oral KS than HIV infected children. Of 11 children who completed courses of chemotherapy, seven (63%) had complete cure sustained over a 1-year follow-up period. KS is potentially curable in this group of children. Chemotherapy regimens are equally effective in HIV-seropositive and HIV-seronegative children. The presentation of HIV-seronegative children with KS differs from adults and HIV-seropositive children. Further research is necessary to determine possible triggers for developing KS in HIV-seronegative children.
Collapse
Affiliation(s)
| | - Kondwani Banda
- Clinical Officer, Queen Elizabeth Central Hospital, Blantyre, Malawi
| | | |
Collapse
|
23
|
Darre T, Mouhari-Toure A, Saka B, Amouzou EGYO, Dare S, Landoh DE, Amegbor K, Pitché P, Napo-Koura G. [Skin disorders seen in anatomical pathology laboratory in Lome, Togo]. Pan Afr Med J 2015; 21:41. [PMID: 26405477 PMCID: PMC4564398 DOI: 10.11604/pamj.2015.21.41.6219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Accepted: 02/07/2015] [Indexed: 11/22/2022] Open
Abstract
Introduction Les affections cutanées restent encore un problème de santé publique dans la majorité des pays en développement. Notre étude s'est fixée comme objectif de déterminer les aspects épidémiologiques et histologiques des dermatoses au Togo. Méthodes Il s'agissait d'une étude descriptive et transversale portant sur les cas de dermatoses diagnostiquées de 2002 à 2013 (10 ans) au laboratoire d'anatomie pathologique (LAP) du CHU- Sylvanus Olympio. Tous les cas d'examen portant sur un prélèvement de peau (biopsie, exérèse, pièces opératoires) ont été colligés de 2002 à 2013 à partir des données des registres dudit laboratoire. Résultats Au cours de la période d’étude, 1119 (7,6%) des 14720 prélèvements reçus au LAP étaient des prélèvements de peau, ce qui correspond à une fréquence annuelle de 111,9 prélèvements. L’âge moyen des patients dont les prélèvements de peau appartenaient était de 35,4 ans et le sex-ratio (H/F) de 1,39. Au plan histologique, les lésions cutanées étaient reparties en dermatoses non tumorales (390 cas, 34,8%), dermatoses tumorales et pseudo tumorales (607 cas, 54,2%) et des dermatoses de diagnostic incertain (122 cas, 10,9%). La lèpre (95 cas, 8,5%) et le carcinome épidermoïde (134 cas, 11,9%) étaient les types histologiques les plus fréquents. Conclusion Les dermatoses tumorales et pseudo tumorales font plus l'objet de demande d'examen anatomopathologique au Togo, ce qui s'explique par la hantise de tumeurs malignes devant toute dermatose tumorale. L'amélioration du plateau technique du LAP (immunohistochimie, immunofluorescence directe) permettra d'accroitre ses capacités diagnostiques.
Collapse
Affiliation(s)
- Tchin Darre
- Laboratoire d'Anatomie et Cytologie Pathologiques, CHU Sylvanus Olympio, Lomé, Togo
| | | | - Bayaki Saka
- Service de Dermatologie, CHU Sylvanus Olympio, Lomé, Togo
| | | | - Sassil Dare
- Services de Chirurgie, CHU Sylvanus, Lomé, Togo
| | | | - Koffi Amegbor
- Laboratoire d'Anatomie et Cytologie Pathologiques, CHU Sylvanus Olympio, Lomé, Togo
| | | | - Gado Napo-Koura
- Laboratoire d'Anatomie et Cytologie Pathologiques, CHU Sylvanus Olympio, Lomé, Togo
| |
Collapse
|
24
|
Abstract
SUMMARY Systematic studies comparing the outcomes of cancer treatment between children with and without HIV are scarce. The literature seems to suggest that, even with present therapeutic advances, prognosis is poor with HIV infection. The aim of this Review was to assess scientific publications from 1990 to present, addressing the difficulties associated with treatment of cancer in children with AIDS and the adaptive changes in therapy. Although much progress has been achieved, further research is needed about antiretroviral and cytotoxic drug interactions, the optimum use of supportive therapy including stem cells and bone marrow transplant, the timing of the initiation of highly active antiretroviral therapy, and the optimum use of protease inhibitors.
Collapse
Affiliation(s)
- Daniela C Stefan
- Department of Paediatrics and Child Health, Tygerberg Hospital and Stellenbosch University, Tygerberg, Cape Town, South Africa.
| |
Collapse
|
25
|
Adebamowo CA, Casper C, Bhatia K, Mbulaiteye SM, Sasco AJ, Phipps W, Vermund SH, Krown SE. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa. J Acquir Immune Defic Syndr 2014; 67 Suppl 1:S17-26. [PMID: 25117957 PMCID: PMC4392880 DOI: 10.1097/qai.0000000000000255] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cancers associated with immunosuppression and infections have long been recognized as a major complication of HIV/AIDS. More recently, persons living with HIV are increasingly diagnosed with a wider spectrum of HIV-associated malignancies (HIVAM) as they live longer on combination antiretroviral therapy. This has spurred research to characterize the epidemiology and determine the optimal management of HIVAM with a focus on low-and middle-income countries (LMICs). Given background coinfections, environmental exposures, host genetic profiles, antiretroviral therapy usage, and varying capacities for early diagnosis and treatment, one can expect the biology of cancers in HIV-infected persons in LMICs to have a significant impact on chronic HIV care, as is now the case in high-income countries. Thus, new strategies must be developed to effectively prevent, diagnose, and treat HIVAM in LMICs; provide physical/clinical infrastructures; train the cancer and HIV workforce; and expand research capacity-particularly given the challenges posed by the limitations on available transportation and financial resources and the population's general rural concentration. Opportunities exist to extend resources supported by the President's Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis, and Malaria to improve the health-care infrastructure and train the personnel required to prevent and manage cancers in persons living with HIV. These HIV chronic care infrastructures could also serve cancer patients regardless of their HIV status, facilitating long-term care and treatment for persons who do not live near cancer centers, so that they receive the same degree of care as those receiving chronic HIV care today.
Collapse
Affiliation(s)
- Clement A. Adebamowo
- Office of Research and Training, Institute of Human Virology Nigeria, Abuja, Nigeria, and Department of Epidemiology and Public Health, Institute of Human Virology and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - Corey Casper
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kishor Bhatia
- AIDS Malignancy Program, Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Sam M. Mbulaiteye
- Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD
| | - Annie J. Sasco
- Centre INSERM U 897-Epidémiologie-Biostatistique, Université de Bordeaux, Inserm U 897-Epidémiologie et Biostatistiques, L’Institut de Santé Publique, d’Épidémiologie et de Développement de l’Université de Bordeaux, Bordeaux, France
| | - Warren Phipps
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Sten H. Vermund
- Institute of Global Health and Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
| | - Susan E. Krown
- AIDS Malignancy Consortium and Memorial Sloan-Kettering Cancer Center (emerita), New York, NY
| |
Collapse
|
26
|
Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014; 8:CD003256. [PMID: 25221796 PMCID: PMC4174344 DOI: 10.1002/14651858.cd003256.pub2] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence.However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients. OBJECTIVES To assess the added advantage of chemotherapy plus HAART compared to HAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and , GATEWAY, the WHO Clinical Trials Registry Platform and the US National Institutes of Health's ClinicalTrials.gov for ongoing trials and the Aegis archive of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014. SELECTION CRITERIA Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens. DATA COLLECTION AND ANALYSIS Two review authors assessed the studies independently and extracted outcome data.We used the risk ratio (RR) with a 95% confidence interval (CI) as the measure of effect.We did not conduct meta-analysis as none of the included trials assessed identical chemotherapy regimens. MAIN RESULTS We included six randomised trials and three observational studies involving 792 HIV-infected adults with severe Kaposi's sarcoma.Seven studies included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi's sarcoma. However, this review was restricted to the subset of participants with severe Kaposi's sarcoma disease.Studies comparing HAART plus chemotherapy to HAART alone showed the following: one trial comparing HAART plus doxorubicin,bleomycin and vincristine (ABV) to HAART alone showed a significant reduction in disease progression in the HAART plus ABV group (RR 0.10; 95% CI 0.01 to 0.75, 100 participants); there was no statistically significant reduction in mortality and no difference in adverse events. A cohort study comparing liposomal anthracyclines plus HAART to HAART alone showed a non-statistically significant reduction in Kaposi's sarcoma immune reconstitution inflammatory syndrome in patients that received HAART plus liposomal anthracyclines (RR 0.49; 95% CI 0.16 to 1.55, 129 participants).Studies comparing HAART plus chemotherapy to HAART plus a different chemotherapy regimen showed the following: one trial involving 49 participants and comparing paclitaxel versus pegylated liposomal doxorubicin in patients on HAART showed no difference in disease progression. Another trial involving 46 patients and comparing pegylated liposomal doxorubicin versus liposomal daunorubicin showed no participants with progressive Kaposi's sarcoma disease in either group.Studies comparing different chemotherapy regimens in patients from the pre-HAART era showed the following: in the single RCT comparing liposomal daunorubicin to ABV, there was no significant difference with the use of liposomal daunorubicin compared to ABV in disease progression (RR 0.78; 95% CI 0.34 to 1.82, 227 participants) and overall response rate. Another trial involving 178 participants and comparing oral etoposide versus ABV demonstrated no difference in mortality in either group. A non-randomised trial comparing bleomycin alone to ABV demonstrated a higher median survival time in the ABV group; there was also a non-statistically significant reduction in adverse events and disease progression in the ABV group (RR 11; 95% CI 0.67 to 179.29, 24 participants).An additional non-randomised study showed a non-statistically significant overall mortality benefit from liposomal doxorubicin as compared to conservative management consisting of either bleomycin plus vinblastine, vincristine or single-agent antiretroviral therapy alone (RR 0.93; 95% CI 0.75 to 1.15, 29 participants). The overall quality of evidence can be described as moderate quality. The quality of evidence was downgraded due to the small size of many of the included studies and small number of events. AUTHORS' CONCLUSIONS The findings from this review suggest that HAART plus chemotherapy may be beneficial in reducing disease progression compared to HAART alone in patients with severe or progressive Kaposi's sarcoma. For patients on HAART, when choosing from different chemotherapy regimens, there was no observed difference between liposomal doxorubicin, liposomal daunorubicin and paclitaxel.
Collapse
Affiliation(s)
- Oluwatoyin F Gbabe
- Community Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Charles I Okwundu
- Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- South African Cochrane Centre, South African Medical Research Council, Tygerberg, South Africa
| | - Martin Dedicoat
- Department of Infection, Birmingham Heartlands Hospital, Birmingham, UK
| | - Esther E Freeman
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
27
|
Krown SE, Borok MZ, Campbell TB, Casper C, Dittmer DP, Hosseinipour MC, Mitsuyasu RT, Mosam A, Orem J, Phipps WT. Stage-stratified approach to AIDS-related Kaposi's sarcoma: implications for resource-limited environments. J Clin Oncol 2014; 32:2512-3. [PMID: 25002726 DOI: 10.1200/jco.2014.55.8999] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Margaret Z Borok
- University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | | | - Corey Casper
- Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
| | - Dirk P Dittmer
- Lineberger Comprehensive Cancer Center and University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Mina C Hosseinipour
- University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi
| | - Ronald T Mitsuyasu
- Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, CA
| | - Anisa Mosam
- Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
| | - Jackson Orem
- Uganda Cancer Institute, Mulago Hospital, and Makarere College of Health Sciences, Kampala, Uganda
| | - Warren T Phipps
- University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Uganda Cancer Institute/Hutchinson Cancer Center Alliance, Kampala, Uganda
| |
Collapse
|
28
|
Adewole I, Martin DN, Williams MJ, Adebamowo C, Bhatia K, Berling C, Casper C, Elshamy K, Elzawawy A, Lawlor RT, Legood R, Mbulaiteye SM, Odedina FT, Olopade OI, Olopade CO, Parkin DM, Rebbeck TR, Ross H, Santini LA, Torode J, Trimble EL, Wild CP, Young AM, Kerr DJ. Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol 2014; 11:251-9. [PMID: 24614139 PMCID: PMC4403794 DOI: 10.1038/nrclinonc.2014.37] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Cancer research in Africa will have a pivotal role in cancer control planning in this continent. However, environments (such as those in academic or clinical settings) with limited research infrastructure (laboratories, biorespositories, databases) coupled with inadequate funding and other resources have hampered African scientists from carrying out rigorous research. In September 2012, over 100 scientists with expertise in cancer research in Africa met in London to discuss the challenges in performing high-quality research, and to formulate the next steps for building sustainable, comprehensive and multi-disciplinary programmes relevant to Africa. This was the first meeting among five major organizations: the African Organisation for Research and Training in Africa (AORTIC), the Africa Oxford Cancer Foundation (AfrOx), and the National Cancer Institutes (NCI) of Brazil, France and the USA. This article summarizes the discussions and recommendations of this meeting, including the next steps required to create sustainable and impactful research programmes that will enable evidenced-based cancer control approaches and planning at the local, regional and national levels.
Collapse
Affiliation(s)
- Isaac Adewole
- Gynecologic Oncology Unit, Department of Obsterics and Gynecology, College of Medicine, University of Ibadan, PMB 5017, GPO, Ibadan, Nigeria
| | | | | | | | | | | | | | | | | | | | - Rosa Legood
- London School of Hygiene and Tropical Medicine, UK
| | | | | | | | | | | | | | | | | | - Julie Torode
- Union for International Cancer Control, Switzerland
| | | | | | | | | |
Collapse
|
29
|
Kruger M, Hendricks M, Davidson A, Stefan CD, van Eyssen AL, Uys R, van Zyl A, Hesseling P. Childhood cancer in Africa. Pediatr Blood Cancer 2014; 61:587-92. [PMID: 24214130 DOI: 10.1002/pbc.24845] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Accepted: 10/09/2013] [Indexed: 12/11/2022]
Abstract
The majority of children with cancer live in low- and middle-income countries (LMICs) with little or no access to cancer treatment. The purpose of the paper is to describe the current status of childhood cancer treatment in Africa, as documented in publications, dedicated websites and information collected through surveys. Successful twinning programmes, like those in Malawi and Cameroon, as well as the collaborative clinical trial approach of the Franco-African Childhood Cancer Group (GFAOP), provide good models for childhood cancer treatment. The overview will hopefully influence health-care policies to facilitate access to cancer care for all children in Africa.
Collapse
Affiliation(s)
- Mariana Kruger
- Department of Paediatrics and Child Health, Tygerberg Hospital, University of Stellenbosch, Cape Town, South Africa
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Chagaluka G, Stanley C, Banda K, Depani S, Nijram'madzi J, Katangwe T, Israels T, Bailey S, Mukaka M, Molyneux E. Kaposi's sarcoma in children: an open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. Eur J Cancer 2014; 50:1472-81. [PMID: 24636877 DOI: 10.1016/j.ejca.2014.02.019] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 01/24/2014] [Accepted: 02/21/2014] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Kaposi's sarcoma (KS) is a common childhood cancer in places where HIV is endemic and access to antiretroviral therapy (ART) is delayed. Despite this there are no randomised trials to compare and assess chemotherapeutic regimens. METHOD An open label, randomised trial comparing intravenous vincristine alone, vincristine and bleomycin and oral etoposide, was carried out in children with Kaposi's sarcoma in the Queen Elizabeth Central Hospital, Blantyre, Malawi. HIV infected children were given ART after 2-3 courses of chemotherapy if they were not already on treatment. Neither HIV nor widespread KS are curable and treatment is aimed at disease reduction and improved quality of life. Tumour reduction was assessed by measuring the size of sentinel KS nodules and quality of life (QoL) by using the Lansky score. Follow up was until death or for one year. FINDINGS 92 children were enrolled of whom 46% were naïve to ART; 10 (11%) were HIV negative. Survival was not influenced by age or gender but was better in the oral etoposide and the vincristine and bleomycin groups. P=0.0045. The group receiving oral etoposide had a better quality of life. Toxicity was not significant, and any drop in haemoglobin or white cell count could have been causally related to HIV infection rather than cytotoxic therapy. CONCLUSION Oral etoposide is a safe, effective treatment to contain KS and improve QoL which can be achieved without many visits to the hospital and intravenous injections.
Collapse
Affiliation(s)
| | | | | | | | | | - Thembie Katangwe
- Queen Elizabeth Central Hospital, Blantyre, Malawi; College of Medicine, Blantye, Malawi
| | - Trijn Israels
- VU University Medical Centre, Amsterdam, The Netherlands
| | | | - Mavuto Mukaka
- The Malawi Liverpool Wellcome Trust Research Laboratories, College of Medicine, Blantyre, Malawi
| | - Elizabeth Molyneux
- Queen Elizabeth Central Hospital, Blantyre, Malawi; College of Medicine, Blantye, Malawi.
| |
Collapse
|
31
|
|
32
|
Dow DE, Cunningham CK, Buchanan AM. A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population. J Pediatric Infect Dis Soc 2014; 3:66-76. [PMID: 24567845 PMCID: PMC3933043 DOI: 10.1093/jpids/pit051] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2013] [Accepted: 06/27/2013] [Indexed: 01/30/2023]
Abstract
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is the etiologic agent responsible for all types of KS. Although the majority of pediatric KS cases occur in sub-Saharan Africa, a rise in pediatric transplant KS has been reported in developed countries. In addition, HHV-8 is increasingly described as an infectious cause of hemophagocytic lymphohistiocytosis in children. Transmission of HHV-8 among children is poorly understood; however, the literature strongly suggests that horizontal transmission plays a critical role. Acute infection with HHV-8 and progression to KS in children may be different than in adults, and diagnosis may be overlooked. Currently, neither adult nor pediatric treatment guidelines exist. This review provides an overview of HHV-8 disease in children as it relates to epidemic KS, transplant KS, and other disease manifestations. The current state of the literature is reviewed and knowledge gaps are identified for future exploration.
Collapse
Affiliation(s)
- Dorothy E. Dow
- Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina,Kilimanjaro Christian Medical Centre, Moshi, Tanzania
| | - Coleen K. Cunningham
- Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina
| | - Ann M. Buchanan
- Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina,Kilimanjaro Christian Medical Centre, Moshi, Tanzania,Duke Global Health Institute, Duke University, Durham, North Carolina
| |
Collapse
|
33
|
Abstract
BACKGROUND Kaposi sarcoma (KS) remains the second most frequently diagnosed HIV-related malignancy (HRM) worldwide and most common HRM in sub-Saharan Africa where HIV is most prevalent and human herpesvirus 8 (HHV-8), the precipitating agent for the development of KS, is endemic. The majority of KS patients would likely benefit from systemic chemotherapy in addition to the initiation of antiretroviral therapy (ART). However, as paediatric staging and treatment criteria are not readily available, there are no uniform treatment criteria. OBJECTIVES To describe the efficacy and effectiveness of current treatment options for HIV-associated KS in ART-treated paediatric populations. SEARCH METHODS We used standard Cochrane methods to search electronic databases and conference proceedings with relevant search terms without limits to language. SELECTION CRITERIA Randomised controlled trials, cohort studies, and case-control studies of HIV-infected infants and children <18 years old treated with ART and diagnosed with KS. DATA COLLECTION AND ANALYSIS Abstracts of all studies identified by electronic or bibliographic scanning were examined independently by two authors. We initially identified 920 references and examined 15 in detail for study eligibility. Data were abstracted independently using a standardised abstraction form. MAIN RESULTS After initially screening 920 titles, 15 full-text articles were closely examined by two authors. We identified four cohort studies that met our inclusion criteria for data extraction, coding, and potential meta-analysis.Using the Newcastle-Ottawa Scale and Cochrane risk of bias assessments, all observational studies had cohorts that were representative of average (treated and untreated) HIV-infected children with Kaposi sarcoma. For all outcomes of interest, no study adjusted for any other potential confounders. Two of four observational studies either explicitly described complete follow up of the study participants and/or described the characteristics of the participants lost to follow up.The use of ART together with a chemotherapeutic regimen versus ART alone appears to increase the likelihood of KS remission in HIV-infected children diagnosed with KS, although data are sparse and not adequately adjusted for staging of disease and comorbidities. Additionally, though data are sparse, the use of ART together with a chemotherapeutic regimen versus chemotherapy alone in some analyses appears to increase the likelihood of KS remission and reduce the risk of death in HIV-infected children diagnosed with KS.In this analysis, we found that the quality of evidence was very low due to small sample sizes and a paucity of paediatric literature. AUTHORS' CONCLUSIONS Data describing the efficacy of different treatment options for pediatric KS, to include chemotherapy and ART, are sparse. However, the use of ART together with a chemotherapy regimen may be superior to the use of ART alone or of chemotherapy alone.
Collapse
Affiliation(s)
- Andrew Anglemyer
- University of California, San FranciscoGlobal Health SciencesSan FranciscoCaliforniaUSA94105
| | - Anurag K Agrawal
- Children's Hospital and Research Center OaklandOncology747 52nd StreetOaklandCaliforniaUSA
| | - George W Rutherford
- University of California, San FranciscoGlobal Health SciencesSan FranciscoCaliforniaUSA94105
| | | |
Collapse
|
34
|
Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. THE LANCET. INFECTIOUS DISEASES 2014; 14:627-39. [PMID: 24406145 DOI: 10.1016/s1473-3099(13)70363-3] [Citation(s) in RCA: 305] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Worldwide, more than three million children are infected with HIV, 90% of whom live in sub-Saharan Africa. As the HIV epidemic matures and antiretroviral treatment is scaled up, children with HIV are reaching adolescence in large numbers. The growing population of adolescents with perinatally acquired HIV infection living within this region presents not only unprecedented challenges but also opportunities to learn about the pathogenesis of HIV infection. In this Review, we discuss the changing epidemiology of paediatric HIV and the particular features of HIV infection in adolescents in sub-Saharan Africa. Longstanding HIV infection acquired when the immune system is not developed results in distinctive chronic clinical complications that cause severe morbidity. As well as dealing with chronic illness, HIV-infected adolescents have to confront psychosocial issues, maintain adherence to drugs, and learn to negotiate sexual relationships, while undergoing rapid physical and psychological development. Context-specific strategies for early identification of HIV infection in children and prompt linkage to care need to be developed. Clinical HIV care should integrate age-appropriate sexual and reproductive health and psychological, educational, and social services. Health-care workers will need to be trained to recognise and manage the needs of these young people so that the increasing numbers of children surviving to adolescence can access quality care beyond specialist services at low-level health-care facilities.
Collapse
Affiliation(s)
- Elizabeth D Lowenthal
- Departments of Pediatrics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA; Department of Paediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Botswana-UPenn Partnership, Gaborone, Botswana
| | - Sabrina Bakeera-Kitaka
- Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda
| | - Tafireyi Marukutira
- Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana
| | - Jennifer Chapman
- Department of Paediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Kathryn Goldrath
- Departments of Pediatrics and Epidemiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
| | - Rashida A Ferrand
- Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK; Biomedical Research and Training Institute, Harare, Zimbabwe.
| |
Collapse
|
35
|
Children with kaposi sarcoma in two southern african hospitals: clinical presentation, management, and outcome. J Trop Med 2013; 2013:213490. [PMID: 24396347 PMCID: PMC3874302 DOI: 10.1155/2013/213490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Accepted: 11/12/2013] [Indexed: 11/17/2022] Open
Abstract
Introduction. In 2010 more than 3 million children with human immunodeficiency virus (HIV) were living in Sub-Saharan Africa. The AIDS epidemic has contributed to an abrupt increase of the frequency of Kaposi sarcoma (KS), especially in Southern Africa. There is a need to describe the clinical features of this disease, its management, and its outcome in HIV positive children in Southern Africa. The aim of the study is to describe two different populations with HIV and KS from two African hospitals in Namibia and South Africa. Material and Methods. A retrospective descriptive study of patients with KS who presented to Tygerberg Hospital (TH) and Windhoek Central Hospital (WCH) from 1998 to 2010. Demographic data, HIV profile, clinical picture of KS, and survival were documented. Results. The frequency of KS declined from 2006 to 2010 in TH but showed an increase in the same period in WCH. Children in TH were diagnosed at a much younger age than those in WCH (44.2 months versus 90 months). Cutaneous lesions were the most common clinical presenting feature, followed by lymphadenopathy, intrathoracic and oral lesions. Conclusions. The clinical characteristics of KS in South Africa and Namibia differ in many aspects between the 2 countries.
Collapse
|
36
|
Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Curr Opin Oncol 2013; 23:463-8. [PMID: 21681092 DOI: 10.1097/cco.0b013e328349428d] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW The purpose of this review is to summarize recent published literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignancy and a leading cancer diagnosis in sub-Saharan Africa (SSA), and to highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment. RECENT FINDINGS There are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively poor cancer treatment infrastructure, leading to late diagnosis and poor access to therapy. The only prospectively randomized trial of chemotherapy compared antiretroviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and vincristine (ABV), and documented a significantly higher rate of tumor regression for the combination along with improvement in quality of life and no adverse effects on HIV control. Other studies suggest that gemcitabine may be an active second-line chemotherapeutic agent after failure of HAART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART with chemotherapy. There are also (primarily retrospective) data suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstitution inflammatory syndrome. SUMMARY Opportunities and need exist for prospective research to establish evidence-based guidelines for the most effective treatments for Kaposi sarcoma in SSA.
Collapse
|
37
|
Cox CM, El-Mallawany NK, Kabue M, Kovarik C, Schutze GE, Kazembe PN, Mehta PS. Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana. Pediatr Blood Cancer 2013; 60:1274-80. [PMID: 23487320 DOI: 10.1002/pbc.24516] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Accepted: 02/04/2013] [Indexed: 12/12/2022]
Abstract
BACKGROUND Kaposi sarcoma (KS) is the most common HIV-associated malignancy in sub-Saharan Africa. The presentation and outcomes of pediatric KS are not well understood. PROCEDURE We performed a retrospective cohort analysis of 81 HIV-infected children with KS at the Baylor Children's Clinical Centres of Excellence in Malawi and Botswana from March 2003 to October 2009. RESULTS Eighty-one children with KS were identified whose median age was 8.0 (inter-quartile range 5.1-11.3) years. KS lesions were presented primarily on the skin (83%), lymph nodes (52%), and oral mucosa (41%). Occasionally disease was limited to the lymph nodes only (10%). Severe immunosuppression (70%), anemia (29%), and thrombocytopenia (17%) were common laboratory findings. Highly active antiretroviral therapy (HAART) was administered to 94% of children, including 77% who received HAART plus chemotherapy. KS immune reconstitution inflammatory syndrome (IRIS) occurred in 22%. Disease status 12 months after KS diagnosis was determined for 69 children: 43% were alive and 57% had died. Severe immunosuppression was independently associated with mortality in multivariate analysis (OR = 4.3; 95% CI 1.3-14.6; P = 0.02). CONCLUSION KS occurs in a significant number of HIV infected children in sub-Saharan Africa. Pediatric KS is distinct from KS in adults. Lymph node involvement was a common manifestation of KS in children, and severe immunosuppression was associated with the highest mortality risk. Though overall mortality was high in children with KS, patients did achieve clinical remission in settings with limited diagnostic and therapeutic resources.
Collapse
Affiliation(s)
- Carrie M Cox
- Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children's Hospital, Houston, Texas 77030-2399, USA.
| | | | | | | | | | | | | |
Collapse
|
38
|
Molyneux E, Davidson A, Orem J, Hesseling P, Balagadde-Kambugu J, Githanga J, Israels T. The management of children with Kaposi sarcoma in resource limited settings. Pediatr Blood Cancer 2013; 60:538-42. [PMID: 23255282 DOI: 10.1002/pbc.24408] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Accepted: 11/01/2012] [Indexed: 11/08/2022]
Abstract
Kaposi sarcoma (KS) is common where HIV infection is endemic. Antiretroviral therapy (ART) has reduced the incidence in well-resourced settings but in some parts of the world access to ART is delayed. These recommendations are for use where only minimal requirements for treatment are available. Consensus was sought for the management of childhood HIV-associated KS in this setting. There are no randomised controlled studies of chemotherapy for KS in children and these recommendations have drawn on consensus of a group of experts and published reports from studies in adults.
Collapse
Affiliation(s)
- Elizabeth Molyneux
- Paediatric Department, College of Medicine, University of Malawi, Blantyre, Malawi.
| | | | | | | | | | | | | |
Collapse
|
39
|
Grzegorzewska AE, Frankiewicz D, Bręborowicz D, Matławska I, Bylka W. Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis. Med Sci Monit 2012; 18:CS67-71. [PMID: 22847205 PMCID: PMC3560695 DOI: 10.12659/msm.883256] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background To date, Kaposi sarcoma has not been mentioned among the adverse effects of triptolide/tripdiolide, ethyl acetate extracts or polyglycosides of the Chinese herbal remedy Tripterygium wilfordii Hook F. Case Report A patient was diagnosed with rheumatoid arthritis at the age of 29 years. She underwent treatment with corticosteroids, methotrexate and gold sodium thiosulfate, and was chronically taking ketoprofen. At the age of 59 years she started to take a powder (≈2 g/day) from a Chinese physician for treatment of rheumatoid arthritis. This powder was supplied to her regularly for 10 years. At the age of 69 years, multiple soft, violaceous to dark-red patches, plaques, nodules and blisters of varying sizes appeared on a background of severely edematous skin on her legs, and later on her arms. Biopsy specimens of the leg lesions were diagnostic for human herpesvirus 8-associated Kaposi sarcoma. Triptolide (235 μg/1 g) and tripdiolide were found in the Chinese powder by the use of Liquid Chromatography Electrospray Ionization Mass Spectrometry. Administration of the powder was stopped and medication with paclitaxel was introduced. General condition of the patient improved and skin lesions diminished significantly. Conclusions This case indicates a possible association between triptolide/tripdiolide chronic intake and development of human herpesvirus 8-associated Kaposi sarcoma. Triptolide/tripdiolide could contribute to development of Kaposi sarcoma by reactivation of latent human herpesvirus 8, permitted by immunosuppression induced by triptolide.
Collapse
Affiliation(s)
- Alicja E Grzegorzewska
- Chair and Department of Nephrology, Transplantology and Internal Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
| | | | | | | | | |
Collapse
|
40
|
Bruder E, Alaggio R, Kozakewich HPW, Jundt G, Dehner LP, Coffin CM. Vascular and perivascular lesions of skin and soft tissues in children and adolescents. Pediatr Dev Pathol 2012; 15:26-61. [PMID: 22420724 DOI: 10.2350/11-11-1119-pb.1] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Vascular anomalies in children and adolescents are the most common soft tissue lesions and include reactive, malformative, and neoplastic tumefactions, with a full spectrum of benign, intermediate, and malignant neoplasms. These lesions are diagnostically challenging because of morphologic complexity and recent changes in classification systems, some of which are based on clinical features and others on pathologic findings. In recent decades, there have been significant advances in clinical diagnosis, development of new therapies, and a better understanding of the genetic aspects of vascular biology and syndromes that include unusual vascular proliferations. Most vascular lesions in children and adolescents are benign, although the intermediate locally aggressive and intermediate rarely metastasizing neoplasms are important to distinguish from benign and malignant mimics. Morphologic recognition of a vasoproliferative lesion is straightforward in most instances, and conventional morphology remains the cornerstone for a specific diagnosis. However, pathologic examination is enhanced by adjunctive techniques, especially immunohistochemistry to characterize the type of vessels involved. Multifocality may cause some uncertainty regarding the assignment of "benign" or "malignant." However, increased interest in vascular anomalies, clinical expertise, and imaging technology have contributed greatly to our understanding of these disorders to the extent that in most vascular malformations and in many tumors, a diagnosis is made clinically and biopsy is not required for diagnosis. The importance of close collaboration between the clinical team and the pathologist cannot be overemphasized. For some lesions, a diagnosis is not possible from evaluation of histopathology alone, and in a subset of these, a specific diagnosis may not be possible even after all assembled data have been reviewed. In such instances, a consensus diagnosis in conjunction with clinical colleagues guides therapy. The purpose of this review is to delineate the clinicopathologic features of vascular lesions in children and adolescents with an emphasis on their unique aspects, use of diagnostic adjuncts, and differential diagnosis.
Collapse
Affiliation(s)
- Elisabeth Bruder
- Institute for Pathology, Hospital of the University of Basel, Basel, Switzerland
| | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected Mozambican children with antiretroviral drugs and chemotherapy. Pediatr Infect Dis J 2011; 30:891-3. [PMID: 21730886 DOI: 10.1097/inf.0b013e318228fb04] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
AIDS-associated Kaposi sarcoma occurs in children, but treatment experience reports are very scarce. A retrospective analysis of 28 children treated with highly active antiretroviral therapy and monthly paclitaxel showed unexpected results with 19 children in complete and sustainable remission, including those with the most severe form. Tolerance and feasibility were good, despite a lack of skilled staff in a low-resource setting.
Collapse
|
43
|
Abstract
OBJECTIVE To determine the prevalence, associated factors, and outcome of HIV-associated malignancies among children enrolling for care at the Baylor-Uganda pediatric HIV clinic in Mulago Hospital, Kampala, Uganda. STUDY DESIGN This was a retrospective case series involving records review of all HIV-infected patients who received care at the Baylor-Uganda clinic in Kampala, Uganda between 1 January 2004 and 31 December 2008. METHODS Medical charts of the clinic patients aged 6 weeks to 18 years were retrieved for data abstraction. Data, including patient's age, sex, diagnosis, type of malignancy, anatomic location of the malignancy, pathology report, baseline laboratory results, and outcome of treatment, were abstracted. Proportions of malignancies among different groups were determined. In addition, Kaplan-Meier survival analysis was conducted. Change in CD4 cell percentages from baseline was assessed with the Wilcoxon signed-rank test. RESULTS A total of 109 children with malignancies presented to the clinic during the study period, making up 1.67% of the total children visiting the clinic. Only two types of malignancies, Kaposi's sarcoma (90.7%) and non-Hodgkin's lymphoma (9.3%), were found. Deaths during follow-up were seen in the first few weeks to months. Upon starting treatment, the CD4 cell percentage increased significantly from a baseline median of 6-14% at 6 months to 15.8% at 12 months of follow-up. CONCLUSION HIV-associated malignancies remain an important cause of morbidity and mortality among HIV-infected children in Uganda. Many affected children die in the first weeks of treatment, but those who survive mount good immunologic recovery.
Collapse
|
44
|
Bibliography. Lymphoma. Current world literature. Curr Opin Oncol 2011; 23:537-41. [PMID: 21836468 DOI: 10.1097/cco.0b013e32834b18ec] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Current world literature. Curr Opin Pediatr 2011; 23:492-7. [PMID: 21750430 DOI: 10.1097/mop.0b013e3283496fc1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Stefan DC, Stones DK, Wainwright L, Newton R. Kaposi sarcoma in South African children. Pediatr Blood Cancer 2011; 56:392-6. [PMID: 21225916 DOI: 10.1002/pbc.22903] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2010] [Accepted: 10/11/2010] [Indexed: 11/11/2022]
Abstract
BACKGROUND The incidence of Kaposi's sarcoma (KS) in sub-Saharan Africa, increased tens of times since the onset of the AIDS epidemic. There is, however, very little literature concerning the clinical features of this disease, its management and outcome in HIV-positive children in Africa. This study describes retrospectively the clinical presentation of the malignancy, its management and outcome, in a series of HIV-positive children. PATIENTS AND METHODS Seventy children with KS and HIV infection were admitted consecutively from January 1998 to December 2009 in South African hospitals. Clinical data were extracted from tumor registries and patient records and analyzed. RESULTS The average age in this series was 73 months. The males/females ratio was 1.59:1. Skin lesions were present in 36 out of 63 cases (57.14%), followed by lymph node lesions (28 cases, 44.44%). The mean CD4+ lymphocyte count was 440 (SD = 385). The average CD4+ percentage was 12.20% (SD = 9.13). Only 14 patients (20%) were taking combined antiretrovirals at the time of diagnosis; a further 35 were given HIV treatment after diagnosis. Thirty-two patients (45.71%) survived only 4 months on average; 10 were lost to follow-up; and 28 (40%) were alive, with an average follow-up of 16 months. Antiretrovirals improved survival (P = 0.001). CONCLUSIONS The often present skin lesions facilitated the diagnosis; lymphadenopathy was less frequently seen than skin lesions. Antiretroviral drugs were associated with higher survival rate. The mortality remains high in spite of antiretrovirals and cytostatics.
Collapse
Affiliation(s)
- D Cristina Stefan
- Department of Paediatrics and Child Health, Tygerberg Hospital, Stellenbosch University, Tygerberg, Cape Town, South Africa.
| | | | | | | |
Collapse
|
47
|
Kohanim S, Daniels AB, Huynh N, Chodosh J. Local treatment of Kaposi sarcoma of the conjunctiva. Int Ophthalmol Clin 2011; 51:183-192. [PMID: 21897150 DOI: 10.1097/iio.0b013e31822d68e8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- Sahar Kohanim
- Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA
| | | | | | | |
Collapse
|
48
|
|